J. Wolter

发表

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

N. Robert, D. Tripathy, S. Shak, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

T. Fleming, L. Norton, J. Baselga, 2001, The New England journal of medicine.

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

D. Wickerham, N. Wolmark, F. Meyers, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.

J. V. Von Roenn, J. Wolter, P. Bonomi, 1988, Seminars in oncology.

Treatment of stage D prostatic carcinoma with megestrol acetate

J. Wolter, P. Bonomi, J. Showel, 1981 .

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin‐D, and cyclophosphamide for advanced sarcoma

D. Schoenfeld, J. Wolter, J. Horton, 1982, Cancer.

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

Anthony Howell, Wolfgang Eiermann, Walter Jonat, 1998, Cancer.

A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

A. Buzdar, C. Vogel, J. Wolter, 1997 .

Significance of DNA abnormalities in primary malignant melanoma and nevi, a retrospective flow cytometric study.

J. V. Von Roenn, J. Coon, J. Wolter, 1986, Cancer research.

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.

J. Wolter, N. Vogelzang, P. Bonomi, 1978, Cancer treatment reports.

Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.

D. Schoenfeld, J. Wolter, M. Cohen, 1980, Cancer treatment reports.

Treatment of histiocytic and mixed lymphomas. A comparison of two, three and four drug chemotherapy

J. Bennett, R. Lenhard, J. Wolter, 1978, Cancer.

A Pilot Study of the Functional Living Index‐Cancer (FLIC) Scale for the Assessment of Quality of Life for Metastatic Lung Cancer Patients: An Eastern Cooperative Oncology Group Study

D. Finkelstein, J. Wolter, B. Cassileth, 1988, American journal of clinical oncology.

A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma

J. Wolter, J. Ruckdeschel, J. Arseneau, 2004, Investigational New Drugs.

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

A. Buzdar, C. Vogel, J. Wolter, 1997, Cancer.

Mithramycin therapy in disseminated germinal testicular cancer.

J. Wolter, S. Taylor, C. Perlia, 1968, JAMA.

Vindesine: Phase II evaluation in colon cancer and description of its platelet stimulating activity

R. Pazdur, J. Wolter, A. Rossof, 2004, Cancer Chemotherapy and Pharmacology.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A Howell, A. Howell, A. Buzdar, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mithramycin treatment of hypercalcemia

J. Wolter, Sa Taylor, C. Perlia, 1970, Cancer.

Management of carcinoid syndrome.

J. Wolter, P. Bonomi, R. Slayton, 1979, Medical and pediatric oncology.

Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.

M. Cobleigh, J. Wolter, S. Taylor, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.

J. Wolter, P. Bonomi, J. Harris, 1985, Seminars in oncology.

Megestrol acetate: first-line therapy for advanced breast cancer.

J. Wolter, P. Bonomi, S. Economou, 1986, Seminars in oncology.

Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.

J. Wolter, W. Shorey, D. Roseman, 1985, Seminars in oncology.

Therapy of malignant melanoma with an imidazole carboxamide and bis‐chloroethyl nitrosourea

R. Lenhard, J. Wolter, M. Costanza, 1972, Cancer.

Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma

J. Wolter, J. Horton, B. Shnider, 1971, Clinical pharmacology and therapeutics.

Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in advanced previously treated breast cancer: an ECOG pilot study.

J. Wolter, S. Taylor, 1981, Medical and pediatric oncology.

Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.

C. Redmond, R. Foster, N. Wolmark, 1981, Cancer treatment reports.

Results with methyl‐CCNU and DTIC in metastatic melanoma

N. Sedransk, D. Schoenfeld, J. Wolter, 1977, Cancer.

Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy

H. Rockette, C. Redmond, D. Wickerham, 2005, Breast Cancer Research and Treatment.

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.

C. Redmond, N. Wolmark, B. Fisher, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of clinical parameters on the results of 13C‐octanoic acid breath tests: examination of different mathematical models in a large patient cohort

M. Camilleri, J. Keller, P. Layer, 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT)

B. Leyland-Jones, W. Eiermann, P. Klein, 2004 .

Treatment of primary breast cancer with chemotherapy and tamoxifen.

C. Redmond, N. Wolmark, B. Fisher, 1981, The New England journal of medicine.

Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen

J. Wolter, D. Tormey, J. Horton, 1994, Cancer.

Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study.

J. Wolter, A. Rossof, P. Bonomi, 1983, Cancer treatment reports.

Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma

J. Wolter, M. Costanza, R. Oberfield, 1976, Cancer.

Clinical study with bleomycin

J. Wolter, S. Taylor, C. Perlia, 1971, Cancer.

Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.

R. Gelman, J. Wolter, D. Tormey, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

G. Wampler, J. Bennett, J. Wolter, 1979, Cancer treatment reports.

Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.

R. Gelman, J. Wolter, D. Tormey, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

T. Fleming, L. Norton, J. Baselga, 1998 .

Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial

R. Gray, J. Wolter, P. Carbone, 1990, Cancer.

Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study

J. Wolter, J. Bagdade, W. Ryan, 2005, Osteoporosis International.

Megestrol acetate as primary hormonal therapy for advanced breast cancer.

J. V. Von Roenn, J. Wolter, H. Muss, 1988, Seminars in oncology.

Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition.

J. Wolter, P. Subbaiah, J. Bagdade, 1990, The Journal of clinical endocrinology and metabolism.

Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas.

J. Wolter, P. Bonomi, R. Slayton, 1978, Cancer treatment reports.

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

N. Robert, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer.

M. Cobleigh, J. Wolter, R. Ghalie, 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study.

J. Winter, M. O’connell, J. Wolter, 1990, Cancer Investigation.

Results with methyl CCNU and DTIC in metastatic melanoma

N. Sedransk, D. Schoenfeld, H. Bingham, 1978 .

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Ennis, Lex, Rian, 2001, The New England journal of medicine.

A randomized comparison of two dosage schedules of methyl CCNU: Three‐week versus six‐week treatments

J. Wolter, W. Dewys, S. Taylor, 1979, Cancer.

Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.

D. Ettinger, D. Finkelstein, J. Wolter, 1985, Cancer treatment reports.

Treatment of stage D prostatic carcinoma with megestrol acetate

J. Wolter, P. Bonomi, J. Showel, 1982, Journal of surgical oncology.

Vincristine, Actinomycin-0, and Cyclophosphamide for Advanced Sarcoma

D. Schoenfeld, J. Wolter, J. Horton, 2006 .

Sequential hormone therapy for advanced breast cancer.

J. V. Von Roenn, J. Wolter, P. Bonomi, 1988, Seminars in oncology.